Part 6/8:
The team has now scaled up production to kilograms of this antibody—a significant milestone toward clinical application. The antibody has been licensed, and clinical trials are scheduled to begin within the next 18 to 24 months. If successful, this could lead to a revolutionary treatment for dengue—an antibody-based therapy that can be administered during the early stages of infection.